These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

394 related items for PubMed ID: 12491513

  • 1. Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.
    Agarwala SS, Kirkwood JM.
    Cancer; 2003 Jan 01; 97(1):121-7. PubMed ID: 12491513
    [Abstract] [Full Text] [Related]

  • 2. Temozolomide and cisplatin in avdanced malignant melanoma.
    Daponte A, Ascierto PA, Gravina A, Melucci M, Scala S, Ottaiano A, Simeone E, Palmieris G, Comella G.
    Anticancer Res; 2005 Jan 01; 25(2B):1441-7. PubMed ID: 15865103
    [Abstract] [Full Text] [Related]

  • 3. A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumours.
    Coker SA, Dandamudi UB, Beelen AP, Crosby NA, Fisher JL, Obrocea M, Ernstoff MS, Lewis LD.
    J Chemother; 2013 Dec 01; 25(6):362-8. PubMed ID: 24093213
    [Abstract] [Full Text] [Related]

  • 4. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
    Daponte A, Ascierto PA, Gravina A, Melucci MT, Palmieri G, Comella P, Cellerino R, DeLena M, Marini G, Comella G, Italian Cooperative Oncology Group.
    Cancer; 2000 Dec 15; 89(12):2630-6. PubMed ID: 11135225
    [Abstract] [Full Text] [Related]

  • 5. Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.
    García M, del Muro XG, Tres A, Crespo C, Valladares M, López JJ, Rifà J, Pérez X, Filipovich E, Germà-Lluch JR.
    Melanoma Res; 2006 Aug 15; 16(4):365-70. PubMed ID: 16845333
    [Abstract] [Full Text] [Related]

  • 6. Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Spieth K, Kaufmann R, Dummer R, Garbe C, Becker JC, Hauschild A, Tilgen W, Ugurel S, Beyeler M, Bröcker EB, Kaehler KC, Pföhler C, Gille J, Leiter U, Schadendorf D.
    Ann Oncol; 2008 Apr 15; 19(4):801-6. PubMed ID: 18178958
    [Abstract] [Full Text] [Related]

  • 7. Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma.
    de Gast GC, Batchelor D, Kersten MJ, Vyth-Dreese FA, Sein J, van de Kasteele WF, Nooijen WJ, Nieweg OE, de Waal MA, Boogerd W.
    Br J Cancer; 2003 Jan 27; 88(2):175-80. PubMed ID: 12610499
    [Abstract] [Full Text] [Related]

  • 8. Temozolomide associated with PEG-interferon in patients with metastatic melanoma: a multicenter prospective phase I/II study.
    Guillot B, Khamari A, Cupissol D, Delaunay M, Bedane C, Dreno B, Picot MC, Dereure O.
    Melanoma Res; 2008 Apr 27; 18(2):141-6. PubMed ID: 18337651
    [Abstract] [Full Text] [Related]

  • 9. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.
    Atkins MB, Gollob JA, Sosman JA, McDermott DF, Tutin L, Sorokin P, Parker RA, Mier JW.
    Clin Cancer Res; 2002 Oct 27; 8(10):3075-81. PubMed ID: 12374674
    [Abstract] [Full Text] [Related]

  • 10. Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.
    Richtig E, Hofmann-Wellenhof R, Pehamberger H, Forstinger Ch, Wolff K, Mischer P, Raml J, Fritsch P, Zelger B, Ratzinger G, Koller J, Lang A, Konrad K, Kindermann-Glebowski E, Seeber A, Steiner A, Fialla R, Pachinger W, Kos C, Klein G, Kehrer H, Kerl H, Ulmer H, Smolle J.
    Br J Dermatol; 2004 Jul 27; 151(1):91-8. PubMed ID: 15270876
    [Abstract] [Full Text] [Related]

  • 11. Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.
    Hwu WJ, Panageas KS, Menell JH, Lamb LA, Aird S, Krown SE, Williams LJ, Chapman PB, Livingston PO, Wolchok JD, Houghton AN.
    Cancer; 2006 Jun 01; 106(11):2445-51. PubMed ID: 16639739
    [Abstract] [Full Text] [Related]

  • 12. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group.
    Kaufmann R, Spieth K, Leiter U, Mauch C, von den Driesch P, Vogt T, Linse R, Tilgen W, Schadendorf D, Becker JC, Sebastian G, Krengel S, Kretschmer L, Garbe C, Dummer R, Dermatologic Cooperative Oncology Group.
    J Clin Oncol; 2005 Dec 10; 23(35):9001-7. PubMed ID: 16260697
    [Abstract] [Full Text] [Related]

  • 13. Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma.
    González Cao M, Malvehy J, Martí R, Conill C, Sánchez M, Martín M, Carrera C, Herrero J, Gascón P, Mellado B, Castel T, Puig S.
    Melanoma Res; 2006 Feb 10; 16(1):59-64. PubMed ID: 16432457
    [Abstract] [Full Text] [Related]

  • 14. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
    Escudier B, Lassau N, Angevin E, Soria JC, Chami L, Lamuraglia M, Zafarana E, Landreau V, Schwartz B, Brendel E, Armand JP, Robert C.
    Clin Cancer Res; 2007 Mar 15; 13(6):1801-9. PubMed ID: 17363536
    [Abstract] [Full Text] [Related]

  • 15. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
    Danson S, Lorigan P, Arance A, Clamp A, Ranson M, Hodgetts J, Lomax L, Ashcroft L, Thatcher N, Middleton MR.
    J Clin Oncol; 2003 Jul 01; 21(13):2551-7. PubMed ID: 12829675
    [Abstract] [Full Text] [Related]

  • 16. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Hauschild A, Garbe C, Stolz W, Ellwanger U, Seiter S, Dummer R, Ugurel S, Sebastian G, Nashan D, Linse R, Achtelik W, Mohr P, Kaufmann R, Fey M, Ulrich J, Tilgen W.
    Br J Cancer; 2001 Apr 20; 84(8):1036-42. PubMed ID: 11308250
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.